Carretero Gmez J, ArvaloLorido JC, Gmez Huelgas R, Garca de Lucas D, Mateos Polo L, Varela Aguilar JM, et al
the specific formulation used in your protocol (compounded versus FDA-approved branded) is discussed at the consultation, where Dr
Evaluations factor in many range of motion ratings, such as the impaired ability to execute skilled movements, disturbance of locomotion, and others
Wang Z, Sun J, Han R et al (2018) Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis